Connection | Profiles RNS

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

JANKU, FILIP

One or more keywords matched the following items that are connected to JANKU, FILIP

Item Type	Name
Academic Article	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Academic Article	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.
Academic Article	KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors.
Academic Article	PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.
Academic Article	Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Academic Article	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
Academic Article	Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses.
Academic Article	Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Academic Article	Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Academic Article	A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma.
Academic Article	FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors.
Academic Article	Ridaforolimus in advanced sarcomas: a leap forward or missed opportunity?
Academic Article	PIK3CA mutations in advanced cancers: characteristics and outcomes.
Academic Article	Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.
Academic Article	Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
Academic Article	Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents.
Academic Article	Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.
Academic Article	Epithelial to mesenchymal transition is associated with rapamycin resistance.
Academic Article	Multiple gene aberrations and breast cancer: lessons from super-responders.
Academic Article	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
Academic Article	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.
Academic Article	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
Academic Article	Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.
Academic Article	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors.
Academic Article	Targeting the PI3K pathway in cancer: are we making headway?
Academic Article	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Concept	TOR Serine-Threonine Kinases
Academic Article	Dual inhibition of BRAF and mTOR in BRAFV600E -mutant pediatric, adolescent, and young adult brain tumors.
Academic Article	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma.
Academic Article	Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid Malignancies.

Search Criteria

TOR Serine Threonine Kinases